Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
3(50%)
Results Posted
200%(2 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
1
17%
Ph phase_3
4
67%

Phase Distribution

1

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
4(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(1)
Terminated(2)

Detailed Status

Active, not recruiting3
Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 34 (66.7%)

Trials by Status

active_not_recruiting350%
completed117%
terminated233%

Recent Activity

3 active trials
Showing 5 of 6
active_not_recruitingphase_3

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

NCT05280548
active_not_recruitingphase_3

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

NCT05206773
terminatedphase_3

A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2

NCT04221451
terminatedphase_3

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

NCT04705051
completedphase_1

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

NCT05718258
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05280548Phase 3

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

Active Not Recruiting
NCT05206773Phase 3

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Active Not Recruiting
NCT04221451Phase 3

A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2

Terminated
NCT04705051Phase 3

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

Terminated
NCT05718258Phase 1

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

Completed
NCT02843035Phase 2

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

Active Not Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6